In vitro trials using CRC cells did show a synergistic effect when statins and EGFR monoclonal antibody were combined [189], but their use in clinical trials did not restore the sensitivity to cetuximab in patients harbouring RAS mutations [190]. Here, EGFR is linked to colorectal carcinoma.